Investigational Drug Steering Committee

The NCI Investigational Drug Steering Committee (IDSC) was established in November 2005. The IDSC is composed of the Steering Committee, ten task forces, and three working groups. Members of the IDSC include the principal investigators of NCI's early drug development grants and contracts, representatives from the Cooperative Groups, a patient advocate, biostatisticians, and NCI staff.

Mission Statement

The IDSC provides NCI with broad external scientific and clinical input on the design and prioritization of phase I and phase II trials with agents for which Cancer Therapy Evaluation Program (CTEP) holds an Investigational New Drug (IND) application. The IDSC aims to increase the predictive value of early phase trials, resulting in the design of more successful phase III trials.

Roster of Investigational Drug Steering Committee (IDSC) members
Lillian Siu, M.D., and Miguel Villalona, M.D., Co-chairs

Task Forces

• Angiogenesis: Chandra Belani, M.D. and Roy Herbst, M.D., Ph.D., Co-chairs
• Biomarkers: Janet Dancey, M.D., and Walter Stadler, M.D., Co-chairs
• Cancer Stem Cell Therapeutics: Charles Erlichman, M.D., William Matsui, M.D. and John Lucio Miele, M.D., Co-chairs
• Clinical Trial Design: Michael LeBlanc, Ph.D. and Mark Ratain, M.D., Co-chairs
• DNA Repair and Programmed Cell Death: Robert DiPaola, M.D. and Adam Dicker, M.D., Ph.D., Co-chairs
• Immunotherapy: Jedd Wolchok, M.D., Ph.D. and Thomas Gajewski, M.D., Co-chairs
• Pharmacology: Edward Newman, Ph.D. and Michelle Rudek, M.D., Co-chairs
• PI3K, AKT, mTOR: Afshin Dowlati, M.D. and Antonio Jimeno, M.D., Ph.D., Co-chairs
• Signal Transduction: Steve Grant, M.D. and John Perentesis, M.D., Co-chairs

Public Summaries:

• July 13, 2012 - Investigational Drug Steering Committee
• March 13, 2012 - Investigational Drug Steering Committee
• October 4-5, 2011 - Investigational Drug Steering Committee
• July 15, 2011 - Investigational Drug Steering Committee
• March 15, 2011 - Investigational Drug Steering Committee
• January 14, 2011 - Investigational Drug Steering Committee
• September 28, 2010 - Investigational Drug Steering Committee
• July 19, 2010 - Investigational Drug Steering Committee
• March 23, 2010 - Investigational Drug Steering Committee
• January 15, 2010 - Investigational Drug Steering Committee
• October 6, 2009 - Investigational Drug Steering Committee
• July 24, 2009 - Investigational Drug Steering Committee

Newsletters:

• IDSC Newsletter May 2012
• IDSC Newsletter February 2012
• IDSC Newsletter October 2011
• IDSC Newsletter June 2011
• IDSC Newsletter February 2011

IDSC Publications:

• April 25, 2012 - IDSC Publication Listing
• Clinical Trial Design TF Recommendations for Phase 2 Clinical Trial Design (July 24, 2009)
• Novel Designs and End Points for Phase II Clinical Trials Meeting Summary (Jan 7, 2007)

NCI Communications:

• A clinical development plan is prepared when NCI decides to study an investigational agent. The plan describes the drug's mechanism of action, disease(s) being targeted, patient characteristics, dose and schedule of the drug, phase(s) of the trial and whether single agent, combination, or additional preclinical studies are sought. The IDSC provides input into Clinical Trials Evaluation Program's (CTEP) clinical development plans. For additional information please see http://ctep.cancer.gov/branches/idb/default.htm

CCCT Contact: Steven Reeves, Ph.D.